Cargando…

CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies

Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodewijk, Iris, Dueñas, Marta, Paramio, Jesus M., Rubio, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579806/
https://www.ncbi.nlm.nih.gov/pubmed/37854601
http://dx.doi.org/10.3389/fimmu.2023.1272681
_version_ 1785121806831583232
author Lodewijk, Iris
Dueñas, Marta
Paramio, Jesus M.
Rubio, Carolina
author_facet Lodewijk, Iris
Dueñas, Marta
Paramio, Jesus M.
Rubio, Carolina
author_sort Lodewijk, Iris
collection PubMed
description Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tumors or the generation of good binders to these antigens, represent a major bottleneck. Specialized cellular mechanisms, such as differential splicing and glycosylation processes, are a good source of neo-antigen expression. Changes in these processes generate surface proteins that, instead of showing decreased or increased antigen expression driven by enhanced mRNA processing, are aberrant in nature and therefore more specific targets to elicit a precise anti-tumor therapy. Here, we present promising TAAs demonstrated to be potential targets for cancer monitoring, targeted therapy and the generation of new immunotherapy tools, such as recombinant antibodies and chimeric antigen receptor (CAR) T cell (CAR-T) or Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) for specific tumor killing, in a wide variety of tumor types. Specifically, this review is a detailed update on TAAs CD44v6, STn and O-GD2, describing their origin as well as their current and potential use as disease biomarker and therapeutic target in a diversity of tumor types.
format Online
Article
Text
id pubmed-10579806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105798062023-10-18 CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies Lodewijk, Iris Dueñas, Marta Paramio, Jesus M. Rubio, Carolina Front Immunol Immunology Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tumors or the generation of good binders to these antigens, represent a major bottleneck. Specialized cellular mechanisms, such as differential splicing and glycosylation processes, are a good source of neo-antigen expression. Changes in these processes generate surface proteins that, instead of showing decreased or increased antigen expression driven by enhanced mRNA processing, are aberrant in nature and therefore more specific targets to elicit a precise anti-tumor therapy. Here, we present promising TAAs demonstrated to be potential targets for cancer monitoring, targeted therapy and the generation of new immunotherapy tools, such as recombinant antibodies and chimeric antigen receptor (CAR) T cell (CAR-T) or Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) for specific tumor killing, in a wide variety of tumor types. Specifically, this review is a detailed update on TAAs CD44v6, STn and O-GD2, describing their origin as well as their current and potential use as disease biomarker and therapeutic target in a diversity of tumor types. Frontiers Media S.A. 2023-10-03 /pmc/articles/PMC10579806/ /pubmed/37854601 http://dx.doi.org/10.3389/fimmu.2023.1272681 Text en Copyright © 2023 Lodewijk, Dueñas, Paramio and Rubio https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lodewijk, Iris
Dueñas, Marta
Paramio, Jesus M.
Rubio, Carolina
CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title_full CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title_fullStr CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title_full_unstemmed CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title_short CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
title_sort cd44v6, stn & o-gd2: promising tumor associated antigens paving the way for new targeted cancer therapies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579806/
https://www.ncbi.nlm.nih.gov/pubmed/37854601
http://dx.doi.org/10.3389/fimmu.2023.1272681
work_keys_str_mv AT lodewijkiris cd44v6stnogd2promisingtumorassociatedantigenspavingthewayfornewtargetedcancertherapies
AT duenasmarta cd44v6stnogd2promisingtumorassociatedantigenspavingthewayfornewtargetedcancertherapies
AT paramiojesusm cd44v6stnogd2promisingtumorassociatedantigenspavingthewayfornewtargetedcancertherapies
AT rubiocarolina cd44v6stnogd2promisingtumorassociatedantigenspavingthewayfornewtargetedcancertherapies